[SCHEDULE 13D/A] Vor Biopharma Inc. SEC Filing

Rhea-AI Filing Summary

Reprogrammed Interchange LLC and Reid Hoffman filed Amendment No. 4 to a Schedule 13D reporting combined beneficial ownership of 1,597,308 shares, equal to 23.3% of Vor Biopharma Inc. common stock after a 1-for-20 reverse stock split. The amendment states the reporting persons reduced their position through multiple open-market sales between August 25, 2025 and October 3, 2025.

The filing lists discrete sales including 99,115 shares sold from September 12, 2025 through October 3, 2025 at weighted average prices ranging roughly from $30.80 to $39.83, plus a series of sales from August 25, 2025 to September 11, 2025 at weighted average prices in the low $40s to high $30s. No contractual arrangements or legal proceedings are reported, and the filing states other previously disclosed Schedule 13D information remains unchanged except as supplemented.

Positive

• Transparent disclosure of specific sale dates, share amounts, and weighted average prices
• Clear reporting that prior Schedule 13D statements remain unchanged except as supplemented

Negative

• Significant reduction from the holders via multiple open-market sales totaling at least 99,115 shares between September 12, 2025 and October 3, 2025
• Concentrated ownership remains at 23.3%, which could mean continued monitoring for further disposals

Insights

Investor Relations Analyst

TL;DR: Major holder disclosed continued open-market sales leaving a 23.3% stake.

The combined holders report beneficial ownership of 1,597,308 shares (23.3%) after a 1-for-20 reverse stock split, and detail multiple open-market sales across late August through early October totaling specific daily share counts and weighted average prices.

These filings clarify ownership and provide transaction-level pricing for the market; watch near-term institutional filings or further Schedule 13D/A updates for any additional reductions or a change in voting arrangements within the next 30-90 days.

Equity Trading Specialist

TL;DR: Sequential block sales at varied prices show staged liquidation rather than a single block sale.

The reported sales are broken into many tranches (e.g., 15,000, 20,000, 32,451 shares) with weighted average prices spanning approximately $30.80 to $42.33 (post-split reporting), indicating execution across multiple days and price levels.

This pattern is consistent with open-market liquidity-driven exits; traders should monitor daily volume and post-trade disclosures for potential short-term price impact over the next few trading sessions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

VOR BIOPHARMA INC.

(Name of Issuer)

Common Stock, par value $.0001 per share

(Title of Class of Securities)

929033108

(CUSIP Number)

Frank Huang, Manager
101 Mission Street, Suite 1000,
San Francisco, CA, 94105
(415) 541-0200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/02/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reprogrammed Interchange LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,597,308.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,597,308.00

11

Aggregate amount beneficially owned by each reporting person

1,597,308.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

23.3 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The number of shares set forth rows 8, 10 and 11 reflect the 1-for-20 reverse stock split of Vor Biopharma Inc. Common Stock effected September 18, 2025 (the "Reverse Stock Split").

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reid Hoffman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,597,308.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,597,308.00

11

Aggregate amount beneficially owned by each reporting person

1,597,308.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

23.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The number of shares set forth rows 8, 10 and 11 reflect the Reverse Stock Split.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $.0001 per share
(b)	Name of Issuer: VOR BIOPHARMA INC.
(c)	Address of Issuer's Principal Executive Offices: 100 Cambridgepark Drive, Suite 101, Cambridge, MASSACHUSETTS , 02140.
Item 1 Comment: This Amendment No. 4 to Schedule 13D amends and supplements the information provided in the previously filed Statement on Schedule 13D filed with the Securities and Exchange Commission on January 7, 2025 and in Amendment No. 1, Amendment No. 2 and Amendment No. 3 thereto filed with the Securities and Exchange Commission on August 29, 2025, September 9, 2025 and September 12, 2025, respectively (collectively, the "Schedule 13D"), jointly on behalf of Reprogrammed Interchange LLC and Reid Hoffman (each a "Reporting Person" and collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain unchanged in all material respects and in full force and effect. Capitalized terms used but not defined herein have the meaning ascribed to such term in the Schedule 13D, as amended. Responses to each item of this Amendment No. 4 to Schedule 13D are incorporated by reference into the response to each other item, as applicable.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable.
Item 4.	Purpose of Transaction
	Item 4 of Schedule 13D is hereby amended and supplemented as follows: From September 12, 2025 through October 3, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outstanding shares of Common Stock of the Issuer. 1. 15,000 shares on September 12, 2025, at a weighted average per share sale price of $35.0811. The share amount and weighted average per share sale price amount reflect the Reverse Stock Split. 2. 20,000 shares on September 15, 2025, at a weighted average per share sale price of $32.815. The share amount and weighted average per share sale price amount reflect the Reverse Stock Split. 3. 22,363 shares on September 16, 2025, at a weighted average per share sale price of $30.8023. The share amount and weighted average per share sale price amount reflect the Reverse Stock Split. 4. 1,400 shares on October 1, 2025, at a weighted average per share sale price of $39.1925. 5. 32,451 shares on October 2, 2025, at a weighted average per share sale price of $39.828. 6. 7,901 shares on October 3, 2025, at a weighted average per share sale price of $37.832.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Amendment No. 4 to the Schedule 13D, and the information set forth or incorporated in Items 2, 3, 4, 6 and 7, is incorporated by reference in its entirety into this Item 5.
(b)	Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets, (ii) shared power to vote or to direct the vote: See line 8 of cover sheets, (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets, and (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
(c)	During the past 60 days, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions. Each share amount and weighted average per share sale price reflects the Reverse Stock Split. 1. 19,367 shares on August 25, 2025, at a weighted average per share sale price of $42,3256. 2. 14,209 shares on August 26, 2025, at a weighted average per share sale price of $41.6165. 3. 30,582 shares on August 27, 2025, at a weighted average per share sale price of $40.1057. 4. 40,317 shares on August 28, 2025, at a weighted average per share sale price of $40.2307. 5. 27,730 shares on September 3, 2025, at a weighted average per share sale price of $39.9222. 6. 22,650 shares on September 4, 2025, at a weighted average per share sale price of $38.5709. 7. 20,000 shares on September 5, 2025, at a weighted average per share sale price of $39.3639. 8. 23,221 shares on September 8, 2025, at a weighted average per share sale price of $39.7949. 9. 22,461 shares on September 9, 2025, at a weighted average per share sale price of $40,0084. 10.17,500 shares on September 10, 2025, at a weighted average per share sale price of $36.3019. 11.14,240 shares on September 11, 2025, at a weighted average per share sale price of $36.6151.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Reprogrammed Interchange LLC

Signature:	/s/ Frank Huang
Name/Title:	Frank Huang, Manager
Date:	10/06/2025

Reid Hoffman

Signature:	/s/ Reid Hoffman
Name/Title:	Reid Hoffman
Date:	10/06/2025

FAQ

What stake do Reprogrammed Interchange LLC and Reid Hoffman report in VOR?

They report combined beneficial ownership of 1,597,308 shares, representing 23.3% of the outstanding common stock (post reverse split).

Did the holders sell shares recently and when?

Yes. The amendment reports open-market sales from August 25, 2025 through October 3, 2025, including specific tranches on September 12, 15, 16, October 1-3, 2025.

What prices were achieved on the reported sales?

Weighted average per-share sale prices reported range roughly from $30.80 to $42.33, with many prices in the high $30s to low $40s (post-split).

Does the filing disclose any contractual arrangements or legal proceedings?

No. Item 6 states Not applicable, and the filing does not report legal proceedings related to the holdings.

How does the reverse stock split affect the reported numbers?

The filing states the share amounts and weighted average prices reflect a 1-for-20 reverse stock split effected on September 18, 2025.